Objective: To explain how to correctly report the results from a cost-effectiveness analysis (CEA).
T ensions from the interplay of constrained budgets and insatiable demand are forcing health care providers and other decision makers to consider whether a new treatment or intervention is cost-effective. 1, 2 In fact, in Canada it is becoming standard practice to approve treatments not only based on clinical effectiveness but also on cost considerations. In turn, researchers have responded by drawing on economic evaluation techniques that translate patient outcome and cost data into useful information for such decisions. However, consumers of this research must be careful, given that economic summary measures that have been proposed and published in the scientific literature may provide misleading clinical and policy implications.
There are many different types of economic evaluations, among them cost-benefit analysis, CEA, cost-utility analysis, and cost-minimization analysis. 3 An easy way to distinguish one from the other is by examining the analyst's choice of patient outcome and asking, "How is it measured?" In cost-benefit analyses, there are typically many outcomes and all outcomes are valued in dollars; this type of analysis is not very popular in health care. In CEA, a single outcome is analyzed. Commonly, the outcome is measured in clinical units such as symptom-free days or outpatient visits. A second form of CEA is cost-utility analysis, which values patient outcomes in QALYs, equal to the number of life years remaining multiplied by a factor reflecting quality of life. In costminimization analysis, only costs are compared, as patient outcomes are assumed to be identical.
The most popular economic evaluation method in health care is CEA. 3 The goal of CEA is to quantify the trade-off between resources used and outcomes gained. CEA determines the relative efficiency of a treatment alternative, while cost-benefit analysis assesses whether a treatment is worthwhile. The attractiveness of CEA lies in its simplicity: one patient outcome is expressed in its natural units (for example, depression-free days) and compared with the resources used. Typically, resources used are measured in dollars, so the summary measure of a CEA involves cost and a patient outcome (for example, $50 for one more depression-free day).
As CEA has been applied to health care, researchers have used predominantly 2 methods of calculating the summary measure-the ACER and the ICER. The ACER captures the average cost per effect (for example, C/E). In contrast, the ICER reports the ratio of the change in cost to the change in effect (for example, DC/DE). For example, when buying one's favourite beverage, often one has a choice of which size to order. The pricing might be $2.40 for a 12-oz beverage and $4.00 for a 40-oz beverage. The ACERs are 20 cents per ounce and 10 cents per ounce for the smaller and larger drink, respectively; the ICER is about 6 cents per additional ounce. At first glance, the difference between the ACER and ICER may seem trivial; however, in practice, the difference can be highly consequential, with the potential to affect patient care.
In this paper, we review some high-profile exchanges in the scientific literature about how CEAs should be reported. We use hypothetical results from a clinical trial to illustrate the points raised in the exchanges and how different methods affect both presentation of findings and formulation of conclusions. We conclude by describing promising new CEA statistics.
Lessons From the Literature

Applied Economic Evaluations
In spite of published claims to the contrary, "currently there is no clear evidence that atypical antipsychotics generate cost savings or are cost-effective in general use among all schizophrenia patients." 4, p 2054 This was the conclusion of a recent review of CEAs of second-generation antipsychotics. The studies' claims of cost-effectiveness were invalidated by methodological problems. Better methods may foster greater confidence in the results of CEAs, but so, too, may better use of existing methods. Methodological commentators have suggested that, some of the limitations in [application of CEA] methods may be owing to the fact that most of the advances in design and statistical techniques for the analysis of cost and cost-effectiveness are published in highly technical economics or biostatistical journals. 4, p 2054 This highlights the importance of developing a general understanding of why different methods give different results and how the results should be interpreted. The call for a wider appreciation of how economic evaluation concepts are applied in mental health is not new. Of the 91 studies, only 6 reported additional costs and effects (consistent with the ICER approach); and looking solely at the 27 randomized controlled trials, only 3 employed an incremental approach. Summarizing their results and the results of others, [6] [7] [8] [9] Evers et al concluded that, "only a few of the articles reviewed were, in our opinion, good examples of economic evaluation." 5, p 171 Further, "the poor quality of the (economic evaluation) studies is not unique to mental health care: other authors have also found that very few studies adhere to the basic principles of economic evaluation." 5, p 171 A review of all economic evaluations published in 2003 found, "a substantial number of clinical trial-based economic studies using statistical methods of poor quality." 10, p 338 As a first step, the quality of CEAs could be improved by clarifying which is the correct CEA statistic to report. It is not clear if the answer is universally known. An early disagreement about whether to use the ACER or the ICER occurred when reporting the results of the first controlled study to show that esophagitis healing with medical antireflux therapy could affect the natural history of peptic stricture disease. Researchers estimated that the average cost to heal a single patient with omeprazole was $1440, compared with $2546 to heal a patient with H2RA. 11 As the ACER estimate for omeprazole was less than the ACER estimate for H2RA, the researchers claimed that omeprazole was more cost-effective. This drew a critical response claiming that the ICER (and not the ACER) was the relevant measure that should have been calculated and considered. 12 In their rejoinder, the authors dismissed the ICER asserting that it "would have been superfluous and potentially misleading." 13, p 304 They argued the ICER was superfluous because, from the ACER data, the ICER could be calculated if necessary. In addition, because the ICER did not consider a per-unit cost, there was no guarantee a new treatment with an economically-attractive ICER was affordable.
Debates such as this one occurred in the context of a renewed interest to improve the quality of economic evaluations reported in the general medical literature. 6, [14] [15] [16] [17] [18] The Health Economics Literature Until 1997, the health economics literature had recommended ICERs be reported, [19] [20] [21] [22] as had health economists writing for clinical audiences. 23 Then 2 articles by Laska et al 24, 25 appeared in the Health Economics journal supporting the usefulness of ACERs. At the same time, though recommending the use of an ICER, 26 the CCOHTA also encouraged readers to explore the ACER methods presented in the article by Laska et al. p 47 Laska et al's 24 first article, which ignited a debate, began with the assertion that the ICER and ACER play an important part in the assessment of competing mental health interventions or treatments. They claimed decision makers could make decisions based on either ACERs or ICERs. 25 In a vigorous refutation, Briggs and Fenn argued that a comparison of ACERs offered little guidance to the efficient choice of treatment because decisions over the choice of treatment should be made based on ICERs. 27 Laska and colleagues 25 had the last word in the exchange, and they concluded the ACER "is a useful summary parameter that characterizes a treatment independent of its comparators . . . Thus (ACERs) play an important role in the evaluation of the cost-effectiveness of treatments." p 503
The exchange helped to emphasize the importance of identifying what the main objective of CEA is. While seemingly esoteric, the ramifications of the methodological debate are not only important to health economics but hold important implications for health care decision makers as well. To the extent that adoption of technologies or implementation of programs rely on the demonstration of cost-effectiveness, these decisions may be swayed by whether an ACER or an ICER is reported. Thus it becomes crucial for clinicians and other decision makers to understand how the ACER and ICER differ, and what this means for decision making.
Decision Making
To illustrate, consider a hypothetical study (see Table 1 ) comparing an exercise intervention to a new treatment for mild depression (with depression-free weeks used as the effectiveness measure It may be difficult to see how economists arguing about stool might affect decisions. However, empirical studies have found that physicians' decision making can be affected by whether the ACER or the ICER is reported. Noting that "physicians are increasingly asked to use cost-effectiveness information when evaluating alterative health care interventions," 32, p 81 Hershey et al presented physicians with ACER or ICER summary measures of 2 screening options in various settings and asked which option they would recommend to their patients. In settings where the clinical scenario of interest was familiar (for example, cervical cancer screening), the presentation of an ACER or an ICER had no effect on physician choices. However, with unfamiliar situations, presenting ICER information significantly reduced selection of the more expensive screening strategy. A key conclusion from this work is that the importance of thinking in incremental terms is not widely understood in the evaluation of clinical alternatives, as demonstrated by the lack of its use in reported studies. If those who report cost-effectiveness results fail to report and defend results based on their incremental consequences, it should not be surprising that physicians who are asked to use these results would not have learned the importance of thinking in incremental terms. The concern this raises is that average-cost information will lead people to underestimate true incremental costs in cases of diminishing returns to scale, and may in turn cause physicians to recommend procedures that are much more costly, and not much more effective, than available alternatives. 32, p 87-88 In other words, the use of the ACER may lead to bad decisions on the part of physicians and other health care decision makers.
Resolution Through Evolution
The focus of CEA should be on estimating the trade-off between extra cost and extra effect. A decision based on CEA must consider whether a new treatment's trade-off is worth it. The ICER quantifies the trade-off of interest; however, it does not indicate whether the trade-off is worth it. The net benefit approach seeks to address this dilemma. 33, 34 The net benefit approach takes CEA one step further by reframing the fundamental economic question. An INB calculation determines whether the net benefit of a new treatment surpasses that of usual care. In general, the INB is calculated by valuing DE in dollars and then subtracting the associated DC. Using the hypothetical data reported in Table 1 , we explore whether the new treatment provides value for money by calculating the INB as:
(0.5 weeks × $l per depression-free week) -$8750
where a value for l must be assumed. What should the analyst use for society's willingness to pay for an additional depression-free week? It is easy to show that unless l > $17 500, the INB in this case will be negative (the extra cost outweighs the value of the extra effects). When l = $17 500, the INB = 0 (see Table 1 ). As shown, 35 , p 419 the INB can be calculated as the difference in net benefits for each treatment option. In other words, INB equals net benefits for a new treatment minus net benefits for exercise. The net benefits for exercise and new treatment are both $741 750 when l = $17 500 (see Table 1 ). If the willingness to pay for one more week free from depression is less than $17 500, the new treatment is not cost-effective. In our example, a new treatment is probably not cost-effective because it produces a week free from mild depression at an extra $17 500; at this price, a year free from mild depression will cost about 52 times this amount or $912 500. If we assume that someone in full health has twice the quality of life as someone with depression, then the new treatment's extra cost per QALY is about $1 825 000. It is likely that society's willingness to pay or l is not this high.
The heavy reliance on the value of l may raise some concerns.
Primarily, how does one ever obtain the value of l? Herein lies the strength of the net benefit approach. It forces decision makers to directly consider the issue of valuing additional patient outcomes. 33 INB can be computed with various ls and analyzed using multiple regression techniques. 36 How sensitive the results are to the assumed l value can be gauged using a CEAC 37, 38 (for a hypothetical example, see Figure 1 ).
The CEAC shows the probability that a new treatment is cost-effective for different values for l (there are different statistical perspectives from which the CEAC can be interpreted and interested readers are referred elsewhere). [39] [40] [41] In this hypothetical example (which differs from the previous example), Figure 1 illustrates the probability that new treatment is cost-effective and is quite sensitive for some l values. For example, at l = $10, the probability that new treatment is cost-effective is nearly 70%; however, at l = $1 it is about 25%. In contrast, when l = 50, the probability of costeffectiveness is nearly 95%. Figure 1 illustrates the region in which results are sensitive to assumptions about l. The most dramatic gains in the height of the curve (from 25% to 95%) occur between l = $1 and $50. While we may never know the real value of l, if it is assumed to be at or above $50, there appears to be a very good chance that a new treatment is cost-effective. The CEAC incorporates the statistical uncertainty of the estimate into its presentation. As a result, it allows the decision maker to consider this variability when viewing the economic results. New research is seeking to provide decision makers with even greater flexibility in interpreting evidence from economic evaluations. 42
Discussion and Conclusion
A quarter century ago, Udvarhelyi et al 6 found that more than 2 out of every 3 economic evaluation articles they reviewed expressed results in average terms. Their paper has been referenced over 260 times; however, ACERs are still reported in economic evaluations generally [43] [44] [45] [46] and in mental health. [47] [48] [49] Current guidelines for economic evaluation continue to promote use of the ICER instead of the ACER, [50] [51] [52] Figure 1 Cost-effectiveness acceptability curve different conclusions. We discussed the clear advantages the ICER provides, motivating why it is considered the standard summary measure in an economic evaluation. We concluded with a brief discussion of net benefit methods and the CEAC. These recent analytical improvements represent important advancements in economic evaluation. First and foremost, this is because the net benefit reframes the cost-effectiveness question to emphasize more dramatically the need to consider society's values in any decision making process.
Résumé : Un guide du clinicien pour corriger l'analyse coûts-efficacité : les rapports coûts-efficacité moyens et différentiels, et les avantages différentiels nets
Objectif : Expliquer le besoin de déclarer correctement les résultats d'une analyse coûts-efficacité (ACE).
Méthodes :
Les résultats d'un essai clinique hypothétique ont été utilisés pour illustrer comment les différentes façons de déclarer les résultats économiques influent sur la présentation des résultats et la formulation des conclusions. Pour fournir un contexte, nous avons examiné des échanges de premier plan de la documentation scientifique.
Résultats : La question essentielle avec laquelle les décideurs sont aux prises a trait aux options introduites par un nouveau produit ou une nouvelle intervention. Spécifiquement, les décideurs sont-ils prêts à payer le coût additionnel pour les résultats additionnels? On ne peut étudier cette question sans une estimation du coût additionnel par résultat additionnel. Les mesures exactes de coûts-efficacité, comme le rapport coûts-efficacité différentiel ou les avantages différentiels nets traitent cette question.
Conclusions :
Comme les décideurs doivent relever le défi de concilier la demande croissante de soins de santé avec la compression des coûts, il sera primordial d'identifier les façons rentables de prodiguer des soins. Les prestataires de soins de santé et autres décideurs ne devraient pas se laisser berner par les résultats d'ACE mal exécutées. Les décisions portant sur l'adoption de produits pharmaceutiques ou la mise en oeuvre de nouveaux programmes ou de nouvelles interventions peuvent être affectées par le choix de la mesure d'un bilan coûts-efficacité. Ainsi, les consommateurs d'ACE doivent avoir une compréhension sommaire de la raison pour laquelle différentes méthodes donnent différents résultats, et de la manière d'interpréter les résultats.
